Published September 1, 2009 | Version v1
Journal article

Response Surface Methodology: An Extensive Potential to Optimize in vivo Photodynamic Therapy Conditions

  • 1. Centre de Recherche en Automatique de Nancy (CRAN), Nancy-University, CNRS, Centre Alexis Vautrin (CAV), Vandoeuvre-les-Nancy (France)
  • 2. Centre de Recherche en Automatique de Nancy (CRAN), Nancy-University, CNRS, Centre Alexis Vautrin (CAV), Vandoeuvre-les-Nancy (France) and GDR 3049 Medicaments Photoactivables-Photochimiotherapie (PHOTOMED)
  • 3. Laboratoire de Sciences et Genie Alimentaires (LSGA), Ecole Nationale Superieure d'Agronomie et des Industries Alimentaires-Institut National Polytechnique de Lorraine (ENSAIA-INPL), Nancy-University, Vandoeuvre-les-Nancy, Nancy (France)
  • 4. Departement de Chimie Physique de Reactions (DCPR), Nancy-University, CNRS, Nancy (France) and GDR 3049 Medicaments Photoactivables-Photochimiotherapie (PHOTOMED)

Description

Purpose: Photodynamic therapy (PDT) is based on the interaction of a photosensitizing (PS) agent, light, and oxygen. Few new PS agents are being developed to the in vivo stage, partly because of the difficulty in finding the right treatment conditions. Response surface methodology, an empirical modeling approach based on data resulting from a set of designed experiments, was suggested as a rational solution with which to select in vivo PDT conditions by using a new peptide-conjugated PS targeting agent, neuropilin-1. Methods and Materials: A Doehlert experimental design was selected to model effects and interactions of the PS dose, fluence, and fluence rate on the growth of U87 human malignant glioma cell xenografts in nude mice, using a fixed drug-light interval. All experimental results were computed by Nemrod-W software and Matlab. Results: Intrinsic diameter growth rate, a tumor growth parameter independent of the initial volume of the tumor, was selected as the response variable and was compared to tumor growth delay and relative tumor volumes. With only 13 experimental conditions tested, an optimal PDT condition was selected (PS agent dose, 2.80 mg/kg; fluence, 120 J/cm2; fluence rate, 85 mW/cm2). Treatment of glioma-bearing mice with the peptide-conjugated PS agent, followed by the optimized PDT condition showed a statistically significant improvement in delaying tumor growth compared with animals who received the PDT with the nonconjugated PS agent. Conclusions: Response surface methodology appears to be a useful experimental approach for rapid testing of different treatment conditions and determination of optimal values of PDT factors for any PS agent.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2009.04.004

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2009.04.004;
PII
S0360-3016(09)00521-5;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
75
Journal Issue
1
Journal Page Range
p. 244-252
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
41027893
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
COMPUTER CODES; DOSIMETRY; DRUGS; GLIOMAS; IN VIVO; MICE; PEPTIDES; RADIATION DOSES; SIMULATION; SURFACES; THERAPY
Descriptors DEC
ANIMALS; DISEASES; DOSES; MAMMALS; MEDICINE; NEOPLASMS; NERVOUS SYSTEM DISEASES; ORGANIC COMPOUNDS; PROTEINS; RODENTS; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.